Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in β-thalassemia

Blood (2008) 112 (3): 875–885.

https://doi.org/10.1182/blood-2007-12-126938

Published: 2008

Includes: Supplemental data

Journal Articles

Prospective Identification of Resistance Mutants to the JAK2 Inhibitor TG101348.

John D. Hood, PhD, Marcela Alomia, Jon Cao, Ph.D., Chun Chow, Ph.D., Hanna Ehab, M.S., Lohse Dan, Ph.D., Mak Chi Ching, Ph.D., McPherson Andy, Ph.D., Noronha Glenn, Ph.D., Tam Betty, Ph.D., Zhu Hong, Ph.D., Richard Soll, Ph.D.

Blood (2007) 110 (11): 2528.

https://doi.org/10.1182/blood.V110.11.2528.2528

Published: 2007

Journal Articles

Selective Inhibition of JAK2 Driven Erythroid Differentiation of Polycythemia Vera Progenitors

Ifat Geron, MS, Annelie Abrahamsson, MS, Charlene Barroga, PhD, Edward Kavelerchik, MD, Jason R. Gotlib, MD MS, John D. Hood, PhD, Jeffrey Durocher, PhD, Chi Ching Mak, PhD, Glen Noronha, PhD, Richard Soll, PhD, Ayalew Tefferi, MD, Kenneth Kaushansky, MD, Catriona H.M. Jamieson, MD PhD

Blood (2007) 110 (11): 1526.

https://doi.org/10.1182/blood.V110.11.1526.1526

Published: 2007

Journal Articles

Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera.

Gerlinde Wernig, MD, Michael G. Kharas, PhD, Rachel Okabe, Sandra A. Moore, Dena S. Leeman, Dana E. Cullen, Maricel Gozo, Elizabeth P. McDowell, Ross L. Levine, John Doukas, Chi Ching Mak, Glenn Noronha, Michael Martin, Yon D. Ko, Benjamin H. Lee, Richard Soll, Ayalew Tefferi, John D. Hood, D. Gary Gilliland

Blood (2007) 110 (11): 556.

https://doi.org/10.1182/blood.V110.11.556.556

Published: 2007

Journal Articles

Primary Cell Experiments with TG101348, a JAK2-Selective Inhibitor, in the Presence of Myeloproliferative Disorder-Associated JAK2V617F, MPLW515L/K, and JAK2 Exon 12 Mutations.

Terra L. Lasho, MT, Christy Finke, John D. Hood, PhD, Richard Soll, PhD, Glenn Noronha, PhD, Ruben A. Mesa, MD, Catriona Jamieson, MD, PhD, Srdan Verstovsek, MD, PhD, Jorge Cortes, MD, Hagop Kantarjian, MD, D. Gary Gilliland, MD, PhD, Ayalew Tefferi, MD, Animesh Pardanani, MBBS, PhD

Blood (2007) 110 (11): 3541.

https://doi.org/10.1182/blood.V110.11.3541.3541

Published: 2007

NARROW

Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in β-thalassemia

Prospective Identification of Resistance Mutants to the JAK2 Inhibitor TG101348.

Selective Inhibition of JAK2 Driven Erythroid Differentiation of Polycythemia Vera Progenitors

Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera.

Primary Cell Experiments with TG101348, a JAK2-Selective Inhibitor, in the Presence of Myeloproliferative Disorder-Associated JAK2V617F, MPLW515L/K, and JAK2 Exon 12 Mutations.

Email alerts

ASH Publications

American Society of Hematology

Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in β-thalassemia

Prospective Identification of Resistance Mutants to the JAK2 Inhibitor TG101348.

Selective Inhibition of JAK2 Driven Erythroid Differentiation of Polycythemia Vera Progenitors

Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera.

Primary Cell Experiments with TG101348, a JAK2-Selective Inhibitor, in the Presence of Myeloproliferative Disorder-Associated JAK2V617F, MPLW515L/K, and JAK2 Exon 12 Mutations.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only